How would GUIDE be expected to change costs, nursing home stays, or mortality?

The short version: the retrieved records do not answer whether GUIDE changes costs, nursing home stays, or mortality, and no amount of reasoning can fill that hole.

The evidence block contains exactly one relevant record: a 2020 scoping review of drug classes and dementia risk [1]. It maps which antihypertensives, statins, and other classes associate with dementia risk, but it says nothing about the GUIDE care model. The other records retrieved are off-topic: a 2018 study of antipsychotic prescribing trends in nursing homes [2], a 2020 study of Medicare bundled payments and dementia spending [3], and a 2020 study of Medicare's BPCI-A program [4]. None of these evaluate GUIDE outcomes.

The retrieval is thin. It surfaced no GUIDE pilot evaluation, no comparison of GUIDE patients to usual care, no cost-effectiveness analysis, no nursing home placement data, no mortality follow-up. That absence is a fact about the search, not a finding about the world. The question of whether GUIDE changes costs, nursing home stays, or mortality remains unanswered by the records retrieved.

What would settle it: a prospective cohort or randomized trial comparing GUIDE-enrolled dementia patients to matched usual-care controls, measuring hospitalization rates, nursing home placement, caregiver burden, and mortality over at least 12 months. No such study appears in the retrieval.

My call: the evidence does not support any conclusion about GUIDE outcomes. Confidence: not clear — the retrieval simply did not reach the relevant literature.